Optimizing Gene Therapies Targeting the CNS to Deliver Safe & Efficacious Treatment Options for Neurological Disorder Patients
Welcome to the 5th Gene Therapy for Neurological Disorders Summit
Accelerating More Transformative Gene Therapies for CNS Disorders
Recent approvals from Sarepta, Bluebird Bio, and PTC Therapeutics, and news of expanding CNS pipelines have highlighted that we are currently on the cusp of a next-generation of neurological gene therapies, and the 5th Gene Therapy for Neurological Disorders Summit is here to help you propel the next wave of innovation.
This meeting will enable you to overcome your Discovery, Preclinical and Clinical Development, and regulatory challenges, from capsid engineering to preclinical model selection, immunogenicity, drug delivery, and regulation; this is the only cover-to-cover, comprehensive 4-day discussion full of need-to-know and practical insights.
Now that the neurological gene therapy field has been given a renewed sense of direction, this is the opportunity for the community to capitalize on the start of a new wave of innovation and optimize the potential for gene therapies targeting neurological disorders.
Vice President and Head of Global Scientific Affairs,GMA
Chief Scientific Officer
Senior Director - Neuroscience External Research
Takeda Pharmaceutical Co. Ltd.